A possible link of oxaliplatin-induced neuropathy with potassium channel deficit

Muscle and Nerve

Volumn 45, Issue 3, 2012, Pages 403-411

  Dimitrov, Alexander G ^a   Dimitrova, Nonna A ^a  

^a INSTITUTE OF BIOPHYSICS AND BIOMEDICAL ENGINEERING   (Bulgaria)

Author keywords

Hyperexcitability; Myelinated axon model; Oxaliplatin; Potassium channels; Sodium channels

Indexed keywords

OXALIPLATIN; POTASSIUM CHANNEL; SODIUM CHANNEL;

ACTION POTENTIAL; ARTICLE; DENSITY GRADIENT; DRUG INDUCED DISEASE; HUMAN; ION TRANSPORT; NERVE CELL EXCITABILITY; NEUROPATHY; PRIORITY JOURNAL; PROCESS MODEL;

ACTION POTENTIALS; COMPUTER SIMULATION; ELECTRIC STIMULATION; HUMANS; MODELS, BIOLOGICAL; MYELIN SHEATH; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; POTASSIUM CHANNELS; RANVIER'S NODES; SODIUM CHANNELS;

EID: 84857072833     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22311     Document Type: Article

References (41)

1. Lombardi L, Gebbia V, Silvestris N, Testa A, Colucci G, Maiello E. Adjuvant therapy in colon cancer. Oncology 2009;77(suppl 1): 50-56.
2. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
3. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-3116.
4. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005;5(suppl 1):S38-46.
5. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25(suppl 5):4-12.
6. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002;29(suppl 15):11-20.
7. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003;30(suppl 15):5-13.
8. Park SB, Goldstein D, Lin CS, Krishnan AV, Friedlander ML, Kiernan MC. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 2009;27: 1243-1249.
9. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009;132: 2712-2723.
10. Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 2005;1:249-258.
11. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007;57:168-185.
12. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin- induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004;29:387-392.
13. Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 2005;146:1027-1039.
14. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002;20:1767-1774.
15. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Periph Nerv Syst 2008;13:27-46.
16. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
17. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29(suppl 15):21-33.
18. Gamelin L, Boisdron-Celle M, Morel A, Gamelin E. Oxaliplatin neurotoxicity [in French]. Bull Cancer 2006;93(suppl 1):S17-22.
19. McKeage MJ, Hsu T, Screnci D, Haddad G, Baguley BC. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 2001;85:1219-1225.
20. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin and axonal Na{thorn} channel function in vivo. Clin Cancer Res 2006;12: 4481-4484.
21. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+)channel kinetics on rat sensory neurons. Eur J Pharmacol 2000;406: 25-32.
22. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001;85:2293-2297.
23. Benoit E, Brienza S, Dubois JM. Oxaliplatin, an anticancer agent that affects both Na{thorn} and K{thorn} channels in frog peripheral myelinated axons. Gen Physiol Biophys 2006;25:263-276.
24. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005;39:128-135.
25. Kagiava A, Tsingotjidou A, Emmanouilides C, Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 2008;29:1100-1106.
26. Dimitrov AG. Internodal sodium channels ensure active processes under myelin manifesting in depolarizing afterpotentials. J Theor Biol 2005;235:451-462.
27. Dimitrov AG. A possible mechanism of repetitive firing of myelinated axon. Pflugers Arch 2009;458:547-561.
28. Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin Neurophysiol 2001;112:1575-1585.
29. Chiu SY, Schwarz W. Sodium and potassium currents in acutely demyelinated internodes of rabbit sciatic nerves. J Physiol 1987;391: 631-649.
30. Shrager P. Action potential conduction recorded optically in normal, demyelinated and remyelinated axons. In: Waxman SG, Kocsis JD, Stys PK, editors. The axon: structure function and pathophysiology. New York: Oxford University Press; 1995.
31. Vabnick I, Messing A, Chiu SY, Levinson SR, Schachner M, Roder J, et al. Sodium channel distribution in axons of hypomyelinated and MAG null mutant mice. J Neurosci Res 1997;50:321-336.
32. Vabnick I, Shrager P. Ion channel redistribution and function during development of the myelinated axon. J Neurobiol 1998;37:80-96.
33. Halter JA, Clark JW Jr. A distributed-parameter model of the myelinated nerve fiber. J Theor Biol 1991;148:345-382.
34. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatininduced neurotoxicity and the development of neuropathy. Muscle Nerve 2005;32:51-60.
35. Chiu SY, Ritchie JM. Evidence for the presence of potassium channels in the paranodal region of acutely demyelinated mammalian single nerve fibres. J Physiol 1981;313:415-437.
36. Roper J, Schwarz JR. Heterogeneous distribution of fast and slow potassium channels in myelinated rat nerve fibres. J Physiol 1989;416: 93-110.
37. Sittl R, Carr RW, Fleckenstein J, Grafe P. Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy. Neurotoxicology 2010;31:694-700.
38. Lersch C, Schmelz R, Eckel F, Erdmann J, Mayr M, Schulte-Frohlinde E, et al. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2002;2:54-58.
39. von Delius S, Eckel F, Wagenpfeil S, Mayr M, Stock K, Kullmann F, et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 2007;25:173-180.
40. Berthold CH, Rydmark M. Electrophysiology and morphology of myelinated nerve fibers. VI. Anatomy of the paranode-node-paranode region in the cat. Experientia 1983;39:964-976.
41. Berthold CH, Rydmark M. Morphology of normal peripheral axons. In: Waxman SG, Kocsis JD, Stys PK, editors. The axon: structure function and pathophysiology. New York: Oxford University Press; 1995. p 13-48.